Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418663 | 1.00 | PTGDR2 (0.45) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL2062948 | 1.00 | PTGDR2 (0.45) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL198311 | 0.98 | PTGDR2 (0.48) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL198081 | 0.98 | PTGDR2 (0.48) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL1825802 | 0.98 | PTGDR2 (0.48) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL30913266 | 0.98 | PTGDR2 (0.48) | PTGDR2LMNAMAPK1PTGDRKMO | |
| Hydrochloric Acid SCHEMBL8869405 | 0.97 | PTGDR2 (0.47) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL2062720 | 0.86 | PTGDR2 (0.42) | PTGDR2USP2CYP1A2HTR1AADRA2A | |
| SCHEMBL28336946 | 0.83 | PTGDR2 (0.43) | PTGDR2LMNAPTGDRKMOUSP2 | |
| SCHEMBL7919662 | 0.83 | PTGDR2 (0.43) | PTGDR2KMOKDM4EPTGS2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358908-B2 | Crystals, preparation method and application of a muscarinic receptor antagonist | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2025-07-15 | — | — | US | claimed |
| EP-3842419-B1 | METHOD OF MAKING THREO GLYCOPYRROLATE TOSYLATE | JOURNEY MEDICAL CORP (US) | 2024-04-03 | — | — | EP | claimed |
| CN-113461585-B | Synthesis process of glycopyrronium bromide | 安徽普利药业有限公司 | 2023-10-31 | — | — | CN | claimed |
| US-20230167107-A1 | CRYSTALS, PREPARATION METHOD AND APPLICATION OF A MUSCARINIC RECEPTOR ANTAGONIST | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2023-06-01 | — | — | US | claimed |
| EP-4144733-A1 | CRYSTAL OF M RECEPTOR ANTAGONIST AS WELL AS PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Beijing Showby Pharmaceutical Co., Ltd. (CN) | 2023-03-08 | — | — | EP | claimed |
| US-11542232-B2 | Process for production of glycopyrronium tosylate | JOURNEY MEDICAL CORPORATION (US) | 2023-01-03 | — | — | US | claimed |
| CN-115397823-A | M receptor antagonist crystal, preparation method and application thereof | 北京硕佰医药科技有限责任公司 | 2022-11-25 | — | — | CN | claimed |
| EP-3842419-A1 | METHOD OF MAKING THREO GLYCOPYRROLATE TOSYLATE | Dermira, Inc. (US) | 2021-06-30 | — | — | EP | claimed |
| US-20210002219-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | SWK FUNDING LLC | 2021-01-07 | — | — | US | claimed |
| US-20200330430-A1 | GLYCOPYRROLATE SALTS | SWK FUNDING LLC | 2020-10-22 | — | — | US | claimed |
| US-20190225580-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | DERMIRA, INC. | 2019-07-25 | — | — | US | claimed |
| US-10294201-B2 | Process for production of glycopyrronium tosylate | DERMIRA, INC. (US) | 2019-05-21 | — | — | US | claimed |
| US-20180186735-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | SWK FUNDING LLC | 2018-07-05 | — | — | US | claimed |
| US-9926270-B2 | Process for production of glycopyrronium tosylate | DERMIRA, INC. (US) | 2018-03-27 | — | — | US | claimed |
| US-20160052879-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | SWK FUNDING LLC | 2016-02-25 | — | — | US | claimed |
| EP-2961734-A1 | GLYCOPYRROLATE SALTS | Dermira, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| WO-2014134510-A1 | GLYCOPYRROLATE SALTS | DERMIRA, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| EP-2485678-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | claimed |
| US-20090005577-A1 | Method of producing 1-substituted 3-pyrrolates | KRAIOUCHKINE NIKOLAI | 2009-01-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002219-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | TPO, GYPA, THRA | PTGDR2 1783/4885LMNA 4690/4885MAPK1 4111/4885 |
| US-20090005577-A1 | Method of producing 1-substituted 3-pyrrolates | GYPA, GIPR, PGA5 | PTGDR2 863/4885LMNA 4465/4885MAPK1 3486/4885 |
| US-20160052879-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | TPO, GYPA, THRA | PTGDR2 1783/4885LMNA 4690/4885MAPK1 4111/4885 |
| US-20230167107-A1 | CRYSTALS, PREPARATION METHOD AND APPLICATION OF A MUSCARINIC RECEPTOR ANTAGONIST | CHRM5, CHRM2, CHRM3 | PTGDR2 1017/4885LMNA 3370/4885MAPK1 1551/4885 |
| US-20200330430-A1 | GLYCOPYRROLATE SALTS | GYPA, GHSR, GALR3 | PTGDR2 594/4885LMNA 4757/4885MAPK1 3956/4885 |
| US-20180186735-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | TPO, GYPA, THRA | PTGDR2 1783/4885LMNA 4690/4885MAPK1 4111/4885 |
| US-10294201-B2 | Process for production of glycopyrronium tosylate | TPO, GYPA, THRA | PTGDR2 1783/4885LMNA 4690/4885MAPK1 4111/4885 |
| US-20190225580-A1 | PROCESS FOR PRODUCTION OF GLYCOPYRRONIUM TOSYLATE | TPO, GYPA, THRA | PTGDR2 1783/4885LMNA 4690/4885MAPK1 4111/4885 |
| US-12358908-B2 | Crystals, preparation method and application of a muscarinic receptor antagonist | CHRM5, CHRM2, CHRM3 | PTGDR2 1017/4885LMNA 3370/4885MAPK1 1551/4885 |
| US-11542232-B2 | Process for production of glycopyrronium tosylate | TPO, GYPA, THRA | PTGDR2 1783/4885LMNA 4690/4885MAPK1 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.